197 related articles for article (PubMed ID: 38154609)
1. Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies.
Najafi S; Mortezaee K
Life Sci; 2024 Feb; 338():122387. PubMed ID: 38154609
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody.
Cheng K; Feng X; Chai Z; Wang Z; Liu Z; Yan Z; Wang Y; Zhang S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835603
[TBL] [Abstract][Full Text] [Related]
3. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.
Chen J; Zhu T; Jiang G; Zeng Q; Li Z; Huang X
Mol Cancer; 2023 Aug; 22(1):131. PubMed ID: 37563723
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
[TBL] [Abstract][Full Text] [Related]
6. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
[TBL] [Abstract][Full Text] [Related]
8. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
9. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
[TBL] [Abstract][Full Text] [Related]
11. Genetically Programmable Vesicles for Enhancing CAR-T Therapy against Solid Tumors.
Li X; Zhu T; Wang R; Chen J; Tang L; Huo W; Huang X; Cao Q
Adv Mater; 2023 May; 35(19):e2211138. PubMed ID: 36814099
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.
Rafiq S; Yeku OO; Jackson HJ; Purdon TJ; van Leeuwen DG; Drakes DJ; Song M; Miele MM; Li Z; Wang P; Yan S; Xiang J; Ma X; Seshan VE; Hendrickson RC; Liu C; Brentjens RJ
Nat Biotechnol; 2018 Oct; 36(9):847-856. PubMed ID: 30102295
[TBL] [Abstract][Full Text] [Related]
13. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
[TBL] [Abstract][Full Text] [Related]
14. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
16. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.
Yuti P; Wutti-In Y; Sawasdee N; Kongkhla K; Phanthaphol N; Choomee K; Chieochansin T; Panya A; Junking M; Yenchitsomanus PT; Sujjitjoon J
Int Immunopharmacol; 2022 Dec; 113(Pt B):109442. PubMed ID: 36435066
[TBL] [Abstract][Full Text] [Related]
17. Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway.
Shen C; Zhang Z; Tian Y; Li F; Zhou L; Jiang W; Yang L; Zhang B; Wang L; Zhang Y
BMC Med; 2021 Nov; 19(1):283. PubMed ID: 34819055
[TBL] [Abstract][Full Text] [Related]
18. Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment.
Yang Z; Pietrobon V; Bobbin M; Stefanson O; Yang J; Goswami A; Alphson B; Choi H; Magallanes K; Cai Q; Barrett D; Wang B; Qi LS; Marincola FM
J Transl Med; 2023 Feb; 21(1):158. PubMed ID: 36855120
[TBL] [Abstract][Full Text] [Related]
19. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
20. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
Front Immunol; 2022; 13():830292. PubMed ID: 35211124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
